Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anti-Microbial Savior BioteQ Co Ltd stock PB Ratio (=3.26) is close to 3-year low of 3.17.
The historical rank and industry rank for Anti-Microbialvior BioteQ Co's PB Ratio or its related term are showing as below:
ROCO:6864'
s PB Ratio Range Over the Past 10 Years
Min: 2.65 Med: 5.4 Max: 16.15
Current: 3.18
During the past 8 years, Anti-Microbialvior BioteQ Co's highest PB Ratio was 16.15. The lowest was 2.65. And the median was 5.40.
ROCO:6864's PB Ratio is ranked worse than 53.38% of 1227
companies
in the Biotechnology industry
Industry Median: 2.93
vs ROCO:6864: 3.18
During the past 12 months, Anti-Microbialvior BioteQ Co's average Book Value Per Share Growth Rate was 87.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 26.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 12.20% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Anti-Microbialvior BioteQ Co was 34.80% per year. The lowest was -3.90% per year. And the median was 11.50% per year.
Back to Basics: PB Ratio
Anti-Microbialvior BioteQ Co (ROCO:6864) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Anti-Microbialvior BioteQ Co PB Ratio Related Terms
Anti-Microbialvior BioteQ Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6864 vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, Anti-Microbialvior BioteQ Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anti-Microbialvior BioteQ Co PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anti-Microbialvior BioteQ Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Anti-Microbialvior BioteQ Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Anti-Microbialvior BioteQ Co (ROCO:6864) has a PB Ratio of 3.17 as of Jul. 16, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Anti-Microbialvior BioteQ Co and its competitors. This is 41% below median its historical median of 5.40. Over the past decade, Anti-Microbialvior BioteQ Co's PB Ratio has ranged from 2.65 to 16.15. According to the industry distribution chart, Anti-Microbialvior BioteQ Co ranks #655 out of 1227 companies in the Biotechnology industry, placing it in the top 53.4%.
Is Anti-Microbialvior BioteQ Co's PB Ratio too high?
Anti-Microbialvior BioteQ Co's current PB Ratio of 3.17 is 41% below median its 10-year median of 5.40. Over the past 10 years, this metric has ranged from a low of 2.65 to a high of 16.15. The Biotechnology industry median PB Ratio is 2.93. Anti-Microbialvior BioteQ Co's value of 3.17 is 8.2% above this industry median. Based on the distribution chart, Anti-Microbialvior BioteQ Co ranks #655 out of 1227 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Anti-Microbialvior BioteQ Co has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Anti-Microbialvior BioteQ Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Anti-Microbialvior BioteQ Co ranks #655 out of 1227 companies for PB Ratio. This places Anti-Microbialvior BioteQ Co in the lower half of its industry. The industry median PB Ratio is 2.93. Anti-Microbialvior BioteQ Co's value of 3.17 is 8.2% above this benchmark. Historically, Anti-Microbialvior BioteQ Co's own PB Ratio has ranged from 2.65 to 16.15 over the past decade. While the company's 10-year median is 5.40 vs. the industry median of 2.93, Anti-Microbialvior BioteQ Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.93, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anti-Microbialvior BioteQ Co's current PB Ratio of 3.17 is 8.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Anti-Microbialvior BioteQ Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anti-Microbialvior BioteQ Co's current PB Ratio is 3.17, which is 41% below median its own 10-year median of 5.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anti-Microbialvior BioteQ Co stock overvalued right now?
Based on GuruFocus' analysis, Anti-Microbialvior BioteQ Co (ROCO:6864) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$25.48, compared to a current price of NT$42.90 — trading 68.4% above its estimated fair value. The current PB Ratio is 3.17, which is 41% below median its 10-year median of 5.40 and 8.2% above the Biotechnology industry median of 2.93. Anti-Microbialvior BioteQ Co's overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Anti-Microbialvior BioteQ Co (ROCO:6864), the current PB Ratio is 3.17 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Anti-Microbialvior BioteQ Co (ROCO:6864) Overvalued in 2026?
Based on GuruFocus' analysis, Anti-Microbialvior BioteQ Co stock appears to be overvalued.
The current stock price of NT$42.90 is trading 68.4% above its estimated GF Value™ of NT$25.48.
GuruFocus considers Anti-Microbialvior BioteQ Co to be Significantly Overvalued.
Key valuation signals for ROCO:6864:
PB Ratio: 3.17 (41% below median its 10-year median of 5.40)
GF Value™: NT$25.48 vs. price of NT$42.90 (68.4% above fair value)
Industry Position: 8.2% above the Biotechnology median (#655 of 1227)
No single metric tells the full story. See the ROCO:6864 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6864 has been successfully added to your 
